How Pharmacists Can Make an Impact When Treating Dedifferentiated Liposarcoma With Brigimadlin
November 11th 2024Brigimadlin is a new oral MDM2-p53 antagonist under investigation as a potential first-line therapy to improve outcomes for patients with advanced or metastatic dedifferentiated liposarcoma.
Read More